Chemotherapy, a key component of standard breast cancer treatments, is commonly recommended for this molecular subtype, while hormonotherapy and targeted therapies are specifically tailored for receptor-positive breast cancers, including the Luminal and HER2+ subtypes (4). The gene discussed is ERBB2; the disease is breast cancer.